Right Ventricular Global Longitudinal Strain and Its Role in the Prediction of Chemotherapy-Induced Cardiovascular Toxicity

Abstract

Chemotherapy-induced cardiovascular toxicity (CTR-CVT) poses a substantial risk to cancer patients, predominantly affecting the left ventricle (LV). However, recent insights underscore the right ventricle's (RV) vulnerability to these deleterious effects. This paradigm shift has prompted a burgeoning interest in systematically evaluating the RV in cancer patients undergoing chemotherapy and radiotherapy. Notably, the RV may manifest signs of dysfunction preceding those in the LV, necessitating meticulous monitoring and early intervention. Over the past few years, studies have increasingly emphasized the importance of scrutinizing the RV in the context of cancer treatments. The early detection of RV dysfunction emerges as a critical factor in preventing progressive damage and enhancing overall cardiac function. The focus on diligent monitoring and timely intervention in the right ventricle highlights a paradigmatic shift in cardio-oncology practices. This abstract underscore the current landscape in which right ventricle dysfunction (RVD) has become a pivotal area of focus within cardio-oncology. By recognizing the susceptibility of the RV to chemotherapy-induced toxicity, clinicians can implement proactive measures to mitigate potential cardiac complications. As the understanding of these dynamics evolves, this heightened awareness promises to shape future strategies for the comprehensive care of cancer patients, emphasizing preserving both left and right ventricular function throughout treatment.